In addition to the numerous adalimumab (Humira) biosimilars that launched this year, multiple new biosimilar products were approved by the FDA in 2023.
In addition to the numerous adalimumab (Humira) biosimilars that launched this year, multiple new biosimilar products were approved by the FDA in 2023.1 These products included an additional adalimumab biosimilar, an IL-6 receptor antagonist for rheumatoid arthritis and juvenile idiopathic arthritis, and a biosimilar to ustekinumab (Stelara) indicated for multiple inflammatory diseases.
Examining the State of Benzoyl Peroxide-Containing Acne Products After Benzene Contamination
April 10th 2024Christopher Bunick, MD, PhD, FAAD, an associate professor of dermatology and a physician-scientist at the Yale School of Medicine in New Haven, Connecticut, presented updates on benzene in BPO at the 2024 American Academy of Dermatology Annual Meeting.
Methotrexate, Leflunomide Linked to Higher Risk of Adverse Pregnancy Outcomes in Patients With RA
April 8th 2024Due to the increased possibility of adverse pregnancy outcomes associated with methotrexate and leflunomid, it is crucial that patients with rheumatoid arthritis (RA) engage in thorough consultations with their physicians regarding pregnancy planning.